Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06372496 · ClinicalTrials.gov registry record · Phase 4

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

A Phase 4 study of Asthma, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 4
Development phase
1,357
Enrollment target
20
Study locations

NCT06372496 is a Phase 4 study of Asthma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 1,357 participants, below the 1,560-participant average among 374 other Asthma trials with a reported enrollment target (13% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06372496, a Phase 4 study of Asthma, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
1,357 participants
Enrollment target
20
Study locations

Study Summary

The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma

Conditions Studied

Asthma

Interventions

  • DRUG Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate
  • DRUG Inhaled corticosteroids/long-acting beta-2 agonists

Study Locations (20)

Florida

  • GSK Investigational Site - Miami
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Miami
  • GSK Investigational Site - North Miami Beach
  • GSK Investigational Site - Orlando
  • GSK Investigational Site - Palm Springs
  • GSK Investigational Site - Port Charlotte
  • GSK Investigational Site - Tallahassee

North Carolina

  • GSK Investigational Site - Asheville
  • GSK Investigational Site - Charlotte

Arkansas

  • GSK Investigational Site - Little Rock

California

  • GSK Investigational Site - Newport Beach

Illinois

  • GSK Investigational Site - Normal

Louisiana

  • GSK Investigational Site - New Orleans

Maine

  • GSK Investigational Site - Bangor

Michigan

  • GSK Investigational Site - Warren

Trial Details

FieldValue
Enrollment Target 1,357 participants
Start Date 2024-04-16
Est. Completion 2026-01-22
Phase Phase 4

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06372496

The ClinicalTrials.gov registry entry for NCT06372496 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 1,357 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,560-participant average among 374 other Asthma trials with a reported enrollment target (13% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate is the first listed.

NCT06372496 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, North Carolina, Arkansas.

Frequently Asked Questions

What is clinical trial NCT06372496 about?

NCT06372496 is a clinical study titled "Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma". The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma

What is the current status of trial NCT06372496?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 1,357 participants. The study started on 2024-04-16. Estimated completion is 2026-01-22.

What conditions does trial NCT06372496 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT06372496?

The interventions under investigation include: Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (DRUG), Inhaled corticosteroids/long-acting beta-2 agonists (DRUG).

Who is sponsoring clinical trial NCT06372496?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06372496 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.